INDEX—VOLUME II STARTS ON PAGE 971 



Streptococcus, bile, effect of on growth of, 572 



classification of, 579-589 



by changes produced on blood media, 



564 

 by fermentation reactions, 569 



growth characters of, 562 



growth requirements of, 562 



haemolysis produced by, 564-569 



h£emolytic group of, antigenic structure 

 of, 575-588 

 chemical structure of, 279, 280, 574- 



677 

 Group A, 575, 576, 579. See also 



Str. pyogenics 

 Group B, 575, 576, 578, 580. See 



also Str. agalactise 

 Group C, 575, 576, 578, 581, 594 

 Group D, 575, 576, 578, 582, 593. 



See also Str. fwcalis 

 Group E, 576, 578, 586, 594 

 Group F, 576, 578, 586, 594 

 Group G, 575, 576, 578, 586, 594 

 Group H, 576, 587, 594 

 Group K, 576, 578, 587, 594 

 Group L, 576, 587, 594 

 Group M, 576, 587, 594 

 Group N, 576, 587, 594. See also 



Str. lactis 

 in normal nasopharynx and tonsils, 



1993, 1994 

 matt and glossy forms of, 301, 577, 595 

 non-hsemolytic variants of, 567 

 smooth and rough forms of, 300, 594, 

 595 



heat resistance of, 572, 583 



in appendicitis, 1497 



in cholecystitis, 1497 



in mastitis, 1494 



in peritonitis, 1498 



in sinusitis, 1499 



in suppurative lesions of the urinary tract, 

 1500 



methylene blue, reduction of by dififerent 

 species of, 572 



morphology of, 560 



motile, 562 



pathogenicity of, 590 



toxin production of, 590 



variation in, 594 



acidominimus, 589 



agalactia:, 581, 598, 1494 

 in mastitis, 1494 

 pathogenicity of, 592, 1494 



bovis, 585, 586, 588 



cremoris, 588 



durans, 585 



dysgalactise, 582 



epidemicus, relation of to Str. pyogenes, 580 



equi, 582 



equinus, 589 



faecalis group of, 572, 583, 593, 600. See 

 also Group D and Str. fiecalis 

 classification of, 583 

 endocarditis in relation to, 1514 

 heat resistance of, 572 

 in water, 2013, 2025, 2028, 2029 

 relation of to Str. lactis, 585 



Streptococcus glycerinaceus, 585 



haemolyticus, 559. See Str. pyogenes 

 inulaceus, 585 

 kefir, 588 

 lactis, 576, 601 

 in milk, 2037 



relation of to fiecalis group, 583-585 

 liquefaciens, 585 

 mitis, 589 



pneumoniie, 559 etjeq., 592, 598 

 antigenic structure of, 572 

 antigenic types of, 1670 



transmutation of, 305 

 antigens of, 279 

 bile solubUity of, 571 

 capsular swelling reaction of, 241 

 capsule formation by, 561 

 chemical structure of, 574 

 diseases caused by, 1496, 1498, 1499, 



1666-1686 

 frequency of types in health and dis- 

 ease, 1670-1675 

 hsemolysin of, 568, 592 

 hyaluronidase production by, 593 

 in normal nasopharynx, 1993-1994 

 morphology of, 560 

 pathogenicity of, 592 

 polysaccharide antigens of, 574 

 aggressive effects of, 1071 

 skin reaction to in pneumonia, 



1685 

 stimulation of antibody forma- 

 tion by, 1119, 1684 

 Type III, bacterial enzyme act- 

 ing on, 173, 1682 

 rough form of, 300, 595 

 saponin solubility of, 571 

 typing of in pneumonia, 1678 

 variations in, 595 

 pyogenes, 559 et seq., 579, 590, 597 



a- and non-haemolytic colonies of, 567 

 antigenic strudiure of, 280, 575-577, 



579 

 capsule formation by, 561 

 chemotherapy in infections with, 



1477, 1485, 1504 

 erythrogenic toxin of, 591, 1464-1469 

 in relation to toxsemic infection, 

 1031 

 fibrinolysin produced by, 591 

 haemolysins of, 566, 590 

 hyaluronic acid production by, 591 

 hyaluronidase production by, 591 

 in wound infection, 1501-1503 

 infections due to, 1462-1506, 1511, 



1666 

 leucocidin of, 590 

 local immunity to, 1180-1182 

 M and T antigens of, 577 

 pathogenicity of, 590 

 presence of in normal throat, 1469, 



1993-1994 

 spreading factor of, 591 

 toxins produced by, 590 

 typing of, by agglutination, 577 



by precipitation, 577 

 variation in, 594 



